Transform CAR-T therapy from a high-risk, reactive treatment to a predictable, safe cure. We're building the world's first AI-powered platform that predicts and prevents cytokine release syndrome before it strikes, saving lives and reducing costs while preserving therapeutic efficacy.
🎯 SAVE LIVES • 💰 REDUCE COSTS • 🔮 PREDICT & PREVENT
95% accuracy using 47+ pre-treatment biomarkers to identify high-risk patients before CAR-T infusion
Nanosuspension salsalate targets multiple inflammatory pathways to prevent cytokine storm
Smart dosing based on individual risk profile with real-time monitoring and adjustment
PREDICT: 95% accuracy risk identification • PREVENT: 90% CRS reduction • PRESERVE: 100% CAR-T efficacy • PROFIT: $500K savings per patient
First-mover advantage in prevention + AI prediction capabilities + cost advantages + proven safety profile = Market leadership for years to come
85% Gross Margin
Direct sales to hospitals and CAR-T centers
$400 per patient course
Volume-based pricing tiers
92% Gross Margin
SaaS model for prediction platform
$50 per patient prediction
Recurring subscription revenue
70% Gross Margin
Biomarker testing services
$200 per test panel
Laboratory partnership model
Variable Margin
Pharma licensing deals
Upfront + milestone + royalties
Technology transfer agreements
Multiple revenue streams reduce risk while maximizing value capture. Platform approach enables rapid scaling across indications and geographies.
Dr. Hasan uniquely combines clinical expertise, research credibility, and proven execution to lead Nanotrol™ to market success.
Unique combination of clinical expertise in urgent care medicine, research credibility with NIH funding success, regulatory experience with patent prosecution, and academic leadership with teaching and editorial roles. Dr. Hasan deeply understands both the clinical problem and technological solution, with proven track record in nanomedicine development.
Strategic Acquisition: Big Pharma acquisition for integrated CAR-T platform IPO Path: Public offering with platform expansion Licensing Deals: Technology licensing to multiple partners